Tezacaftor

CFTR corrector

Phase of research

FDA-/EMA-approved for Cystic Fibrosis

How it helps

Restore CFTR Function

General information

N/A

Synonyms

VX-661

Marketed as

Dietary sources

N/A

Structure not available

C26H27F3N2O6

Drug-Mutation Relation

results for D1152H / F508del
See all data on Tezacaftor

Treats

Mutation Link Tested on Impact factor Notes
F508del/F508del A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis humans 4.29 In combination with ivacaftor as Symdeko®.
F508del/F508del Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del humans 79.26 In combination with ivacaftor as Symdeko®.
F508del/F508del Study of VX-661 combined with ivacaftor in adults with cystic fibrosis (Vertex VX-661-103) humans N/A In combination with ivacaftor as Symdeko®.
F508del/F508del Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR humans 16.49 Better in combination with ivacaftor as Symdeko®.
F508del/F508del VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. humans 70.67 In combination with ivacaftor. Better in combination with ivacaftor plus elexacaftor.
F508del/F508del VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with ivacaftor and VX-659.
F508del/F508del Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with VX-440 and ivacaftor.
F508del/F508del Phase 2 study of VX-152 combination drug in people with cystic fibrosis (Vertex VX-152-102) humans N/A In combination with VX-152 and ivacaftor.
F508del/D1152H Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators. human cell cultures 4.12
F508del/D1152H Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Phe508del and a Residual Function Mutation humans 79.26 In combination with ivacaftor as Symdeko®. Better than ivacaftor alone.
F508del/D1152H A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis humans 4.29 In combination with ivacaftor as Symdeko®.
F508del/F508del Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators. human cell cultures 4.12

Does not treat

Mutation Link Tested on Impact factor Notes